90 related articles for article (PubMed ID: 7915203)
1. Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/neu proto-oncogene in vitro.
Fisk B; Chesak B; Pollack MS; Wharton JT; Ioannides CG
Cell Immunol; 1994 Sep; 157(2):415-27. PubMed ID: 7915203
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene.
Ioannides CG; Fisk B; Fan D; Biddison WE; Wharton JT; O'Brian CA
Cell Immunol; 1993 Oct; 151(1):225-34. PubMed ID: 7691418
[TBL] [Abstract][Full Text] [Related]
3. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
4. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein.
Disis ML; Smith JW; Murphy AE; Chen W; Cheever MA
Cancer Res; 1994 Feb; 54(4):1071-6. PubMed ID: 7508819
[TBL] [Abstract][Full Text] [Related]
5. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
6. TCR V beta 3+ and V beta 6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers.
Peoples GE; Yoshino I; Douville CC; Andrews JV; Goedegebuure PS; Eberlein TJ
J Immunol; 1994 May; 152(10):4993-9. PubMed ID: 7909829
[TBL] [Abstract][Full Text] [Related]
7. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer.
Yoshino I; Peoples GE; Goedegebuure PS; Maziarz R; Eberlein TJ
J Immunol; 1994 Mar; 152(5):2393-400. PubMed ID: 8133050
[TBL] [Abstract][Full Text] [Related]
8. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer.
Yoshino I; Goedegebuure PS; Peoples GE; Parikh AS; DiMaio JM; Lyerly HK; Gazdar AF; Eberlein TJ
Cancer Res; 1994 Jul; 54(13):3387-90. PubMed ID: 7912166
[TBL] [Abstract][Full Text] [Related]
9. Shared T cell epitopes in epithelial tumors.
Peoples GE; Smith RC; Linehan DC; Yoshino I; Goedegebuure PS; Eberlein TJ
Cell Immunol; 1995 Sep; 164(2):279-86. PubMed ID: 7656335
[TBL] [Abstract][Full Text] [Related]
10. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.
Zaks TZ; Rosenberg SA
Cancer Res; 1998 Nov; 58(21):4902-8. PubMed ID: 9809997
[TBL] [Abstract][Full Text] [Related]
11. Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers.
Peoples GE; Anderson BW; Lee TV; Murray JL; Kudelka AP; Wharton JT; Ioannides CG
Clin Cancer Res; 1999 Dec; 5(12):4214-23. PubMed ID: 10632363
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides.
Ioannides CG; Fisk B; Jerome KR; Irimura T; Wharton JT; Finn OJ
J Immunol; 1993 Oct; 151(7):3693-703. PubMed ID: 7690810
[TBL] [Abstract][Full Text] [Related]
14. Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8.
Lustgarten J; Theobald M; Labadie C; LaFace D; Peterson P; Disis ML; Cheever MA; Sherman LA
Hum Immunol; 1997 Feb; 52(2):109-18. PubMed ID: 9077559
[TBL] [Abstract][Full Text] [Related]
15. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer.
Goedegebuure PS; Douville CC; Doherty JM; Linehan DC; Lee KY; Ganguly EK; Eberlein TJ
Cell Immunol; 1997 Feb; 175(2):150-6. PubMed ID: 9023420
[TBL] [Abstract][Full Text] [Related]
17. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
18. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells.
Kawashima I; Tsai V; Southwood S; Takesako K; Sette A; Celis E
Cancer Res; 1999 Jan; 59(2):431-5. PubMed ID: 9927058
[TBL] [Abstract][Full Text] [Related]
19. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.
Fisk B; Blevins TL; Wharton JT; Ioannides CG
J Exp Med; 1995 Jun; 181(6):2109-17. PubMed ID: 7539040
[TBL] [Abstract][Full Text] [Related]
20. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
